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these alterations may be early events in carcinogenesis. 
Quantifi cation of these parameters in Barrett’s esopha-
gus might be useful to identify patients at higher risk for 
progression to cancer.
© 2007 The WJG Press. All rights reserved.
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Esophageal cancer is still one of  the most widespread 
diseases, and the early diagnosis of  esophageal carcinoma 
correlates closely with improvement in prognosis. Barrett's 
esophagus (BE) is a precancerous condition of  the lower 
esophagus in which the normal stratified squamous 
epithelium is replaced with specialized metaplastic 
columnar epithelium. Barrett’s mucosa represents a type 
of  epithelium that is completely different from the normal 
esophageal mucosa. BE is the main precancerous condition 
in the development of  esophageal adenocarcinoma[1,2]. 
BE is diagnosed in up to 20% of  patients with 
documented chronic gastroesophageal reflux disease 
(GERD). Fol low-up studies have shown that BE 
has a 30- to 125-fold increased risk of  developing 
into an adenocarcinoma, which emerges at a rate of  
approximately one cancer per 100 patient-years[3]. Barrett’s 
adenocarcinoma displays the most rapidly increasing 
incidence for gastrointestinal tract cancer in the Western 
world. Diagnosis of  Barrett’s adenocarcinoma is usually 
made late, and consequently, is associated with poor 
prognosis[4-6]. 
Carcinogens are one of  the inducing etiological 
factors for esophageal adenocarcinoma. Glutathione 
S-transferase (GST), a family of  detoxification enzymes, 
plays an important role in the prevention of  cancer by 
detoxifying numerous potentially carcinogenic compounds, 
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Abstract
AIM: To investigate the role of glutathione S-transferase 
(GST) and matrix metalloproteinase-9 (MMP-9) expres-
sions in the development and progression of refl ux es-
ophagitis-Barrett’s metaplasia-dysplasia-adenocarcinoma 
sequence in the esophagus.
METHODS: GST and MMP-9 expressions were analyzed 
in 51 paraffi n-embedded tissue samples by immunohisto-
chemistry including patients with refl ux esophagitis (n = 
7), Barrett’s metaplasia (n = 14), Barrett and esophagi-
tis (n = 8), Barrett and dysplasia (n = 7), esophageal 
adenocarcinoma (n = 8) and a control group without 
any histological changes (n = 7). Immunostaining was 
determined semiquantitatively. Statistical analysis with 
one-way ANOVA, LSD test and correlation analysis were 
performed. P  value of < 0.05 was considered signifi cant.
RESULTS: GST expression was signifi cantly higher while 
MMP-9 expression was significantly lower in control 
group compared to Barrett’s metaplasia and the other 
groups. No major changes were observed between Bar-
rett, esophagitis, and Barrett and concomitant esophagi-
tis. Barrett and concomitant dysplasia, and adenocarci-
noma revealed a signifi cant lower expression of GST and 
higher levels of MMP-9 compared to all other groups. 
Adenocarcinoma showed almost no expression of GST 
and signifi cantly higher levels of MMP-9 than Barrett and 
concomitant dysplasia. Alterations of GST and MMP-9 
were inversely correlated (r  = - 0.82).
CONCLUSION: Decreased GST and increased ex-
pression of MMP-9 in Barrett’s metaplasia-dysplasia-
adenocarcinoma sequence as compared to normal tissue 
suggest their association with esophageal tumorigenesis. 
Loss of GST and gain of MMP-9 in Barrett with dyspla-
sia compared to non-dysplastic metaplasia indicate that 
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which can cause oxidative damage to cells[7]. Therefore, a 
reduction in these anti-oxidant enzymes can increase the 
risk of  carcinogenesis[8]. Decreased GST enzyme activity 
has been reported in BE, and an inverse correlation was 
demonstrated between GST enzyme activity and tumor 
incidence in the gastrointestinal tract[9,10]. It has been 
suggested that down-regulation of  GST expression could 
be an early event in the development of  BE[11].
The degradation of  the extracellular matrix (ECM), 
including the basement membrane, which is a specialized 
matrix composed of  type ? collagen, laminin, entactin, 
proteoglycans and glycosaminoglycans, is an important 
feature of  cancer cell invasion, and proteolytic enzymes 
play an important role in this event[12]. 
Several human solid tumors have been reported to 
have increased levels of  proteolytic enzymes in cancer 
tissue, strongly suggesting that proteases may be important 
in tumor invasion and metastasis. With respect to the 
gastrointestinal tract, we have previously demonstrated 
that proteolytic enzymes may have a role not only in the 
process of  gastric[13] or colorectal cancer invasion[14], but 
also in the progression of  gastrointestinal precancerous 
changes into cancer[15]. 
Matrix metalloproteinases (MMPs) degrade compo-
nents of  the ECM and connective tissue surrounding the 
tumor cells and the basement membrane. MMPs are clas-
sifi ed as gelatinases, collagenases, stromelysins, membrane-
type matrix metalloproteinases, based mainly on the in vivo 
substrate specifi city of  the individual MMP. It was initially 
believed that MMPs, via breakdown of  the physical bar-
rier, were primarily involved in tumor invasion[16]. There 
is growing evidence, however, that the MMPs have an 
expanded role, as they are important for the creation and 
maintenance of  a microenvironment that facilitates growth 
and angiogenesis of  tumors at primary and metastatic 
sites[17,18].
Type ? collagen is an important protein of  the 
basement membrane. Type ? collagenase, matrix 
metalloproteinase-9 (MMP-9) (gelatinase B), has been 
reported to be especially important in the process of  
tumor invasion and metastasis [19,20]. Several MMPs 
(gelatinase A: MMP-2; stromelysin: MMP-3; matrilysin: 
MMP-7; metal loelastase: MMP-12; col lagenase-3: 
MMP-13) are expressed by tumor cells in esophageal 
squamous cell and adenocarcinomas, suggesting that 
these MMPs are responsible for tumor aggressiveness and 
prognosis in human esophageal carcinomas[21-24].
In the specifi c case of  MMP-9, increased expressions 
have been observed in gastric cancer[25-27] and esophageal 
squamous cell carcinoma[28-30], but its behaviour in 
esophageal adenocarcinoma and in preinvasive lesions of  
esophageal carcinogenesis is still uncertain.
On the other hand, GST and MMP-9 as actors either 
in cancer prevention or in carcinogenesis have not been 
evaluated in the same experimental setting. Therefore, the 
aim of  the present study was to investigate the role of  
GST and MMP-9 expressions using immunohistochemical 
analysis in the development and progression of  reflux 
esophagitis-BE-dysplasia-adenocarcinoma sequence in the 
esophagus.
MATERIALS AND METHODS
Tissue specimens were obtained endoscopically from in- 
and outpatients with upper abdominal complaints at the 
2nd Department of  Medicine, Semmelweis University, 
Budapest. 
Informed consent was obtained from all patients 
involved in the study, and a local ethical permission has 
been obtained. The patients comprised of  33 males 
and 18 females. The median age was 64 years with a 
range from 22 to 83 years. The endoscopic specimens 
were fixed in formalin and embedded in paraffin wax, 
sliced serial step sections of  4 μm thickness. GST and 
MMP-9 immunohistochemical expressions were analyzed 
in a total of  51 paraffin-embedded tissue samples by 
immunohistochemistry including patients with reflux 
esophagitis (n = 7) (4 males, 3 females, mean age 61 years, 
range 36-68 years); BE (n = 14) (9 males, 5 females, mean 
age 66 years, range 48-69 years); BE and esophagitis (n = 8) 
(6 males, 2 females, mean age 67 years, range 55-71 years); 
BE and dysplasia (n = 7) (4 males, 3 females, mean age 68 
years, range 52-72 years); and esophageal adenocarcinoma 
(n = 8) (6 males, 2 females, mean age 71 years, range 64-83 
years). Esophageal biopsies from patients with functional 
dyspepsia without any histological changes were used as 
controls (n = 7) (4 males, 3 females, mean age 49 years, 
range 22-56 years). 
GST immunohistochemistry
The 4 micron thick tissue sections were dewaxed and 
rehydrated. Endogenous peroxidase activity was blocked 
by incubation for 30 min at room temperature in 3% 
hydrogen peroxide. After washing the sections 3 times in 
PBS for 5 min, non-specifi c blocking was done with 1% 
BSA-PBS solution for 10 min at room temperature. Next, 
the slides were incubated with diluted polyclonal rabbit 
anti-human GSTP1 antibody (1 μL GSTP1 antibody and 
150 μL PBS) (Clone: A3600, DAKO) at 37℃ for 60 min 
in a humidified chamber. After washing the specimens 
3 times in PBS, signal conversion was carried out with 
the LSAB2 system (DAKO) as described in the manual. 
Finally, haematoxylin co-staining was performed.
MMP-9 immunohistochemistry
After deparaffi nization in xylene and rehydration through 
graded ethanol, endogenous peroxidase activity was 
blocked by incubation for 30 min at room temperature 
in 3% hydrogen peroxide. After washing the sections 
3 times in PBS for 5 min, non-specific blocking was 
carried out with 1% BSA-PBS solution for 10 min at 
room temperature. Next, the slides were incubated with 
optimally diluted monoclonal anti-human MMP-9 antibody 
(Clone: 36 020.111, R&D Systems) at 37℃ for 60 min in 
a humidifi ed chamber. After washing the samples 3 times 
in PBS, signal conversion was carried out with the LSAB2 
system (DAKO) as described in the manual. Finally, 
haematoxylin co-staining was performed.
Immunohistochemical analysis of GST and MMP-9
Known immunohistochemically-positive tissue sections 
were used as positive controls, and negative control 
sections were processed immunohistochemically after 
having replaced the primary antibody by PBS. None 
of  the control sections exhibited immunoreactivity. 
Immunostaining was determined semiquantitatively, as 
previously described[31]. Essentially, the intensity of  staining 
for GST and MMP-9 under a light microscope was graded 
from 0 to 3, denoting no staining or light, moderate, or 
intense staining. An immunohistochemical staining score 
was calculated for each histologic area by multiplying 
the staining intensity level (0 to 3) by the proportion of  
cells in each area staining with the given intensity. The 
immunohistochemical staining score for an area with 100% 
of  cells with intense staining, for example, would be 1 × 3, 
equalling 3, whereas an area with 50% cells with moderate 
staining and 40% without any staining would have a score 
of  0.5 × 2 plus 0.4 × 1, equalling 1.4. Two independent 
investigators without knowledge of  the clinical outcomes 
evaluated the degree of  immunohistochemical staining 
intensity. There was less than 5% variance between the 
results of  the two counts.
Statistical analysis
Statistical analysis with one-way ANOVA, LSD test and 
correlation analysis were performed by the Statistica for 
Windows 4.3 program package. P value of  < 0.05 was 
considered signifi cant.
RESULTS
The immunohistochemical expression scores of  GST 
and MMP-9 in various types of  mucosal lesions of  the 
esophagus (n = 51) are shown in Tables 1 and 2. 
Expression of  GST (Table 1) in normal esophageal 
epithelium (control group) was significantly higher 
compared to BE and the other groups (P < 0.00001), while 
no major changes were observed between BE, esophagitis, 
and BE with concomitant esophagitis.
BE with concomitant dysplasia, and adenocarcinoma 
revealed a signifi cantly lower expression of  GST compared 
to all other groups (P < 0.005). Adenocarcinoma showed 
almost no expression of  GST and a significantly lower 
expression than BE and concomitant dysplasia (P < 0.05).
The semiquantitative score of  MMP-9 (Table 2) in 
the normal esophageal epithelium (control group) was 
signifi cantly lower compared to BE and the other groups 
(P < 0.00001); while no major changes were observed 
between BE, esophagitis, and BE with concomitant 
esophagitis.
Significantly higher expression levels of  MMP-9 
have been observed in BE with concomitant dysplasia 
and adenocarcinoma compared to all other groups (P < 
0.05). Finally, MMP-9 expression was signifi cantly higher 
in adenocarcinoma compared to BE and concomitant 
dysplasia (P < 0.05). 
GST and MMP-9 were expressed mainly within the 
cytoplasm and cytoplasmic membranes of  the esophageal 
epithelium in dysplastic or adenocarcinoma cells (Figures 
1 and 2). Immunoexpressions of  GST and MMP-9 in the 
esophageal tissues were inversely correlated (r = - 0.82; P 
= 0.001) (Figure 3).
DISCUSSION
Despite advances in diagnosis and therapy, esophageal 
adenocarcinoma remains an aggressive and usually lethal 
tumor. BE is the main precancerous condition in the 
development of  esophageal adenocarcinoma; however, 
its pathogenesis is poorly understood. BE typically 
progresses from metaplasia with atypia to dysplasia and 
adenocarcinoma. It is of  great clinical importance to 
correctly identify changes with a high risk for malignant 
transformation, as high-grade dysplasias and early 
adenocarcinomas in patients with BE have a high chance 
for cure[32]. The identifi cation of  high-risk lesions in BE by 
histologic evaluation has drawbacks, especially regarding 
sampling errors and frequent intra- and inter-observer 
discrepancies in the histopathologic grading/staging of  
these lesions. Several new biomarkers are being tested to 
help in better determining the risk of  cancer development. 
Table 1  GST immunohistochemical expression according to a 
semiquantitative score in various types of mucosal lesions of the 
esophagus
aP < 0.00001 vs the other groups; bP < 0.005 vs the other groups (normal 
epithelium, refl ux esophagitis, barrett's metaplasia, barrett's metaplasia and 
Refl ux esophagitis); cP < 0.05 vs barrett's metaplasia and dysplasia.
Table 2  MMP-9 immunohistochemical expression according to 
a semiquantitative score in various types of mucosal lesions of 
the esophagus
bP < 0.00001 vs the other groups; aP < 0.05 vs the other groups (normal 
epithelium, refl ux esophagitis, barrett's metaplasia, barrett's metaplasia and 
Refl ux esophagitis); cP < 0.05 vs barrett's metaplasia and dysplasia.
Histology              Score (mean ± SD)
Normal epithelium (Control group)a   2.85 ± 0.24
(n = 7)  
Refl ux esophagitis     1.14 ± 0.24
(n = 7)
Barrett’s metaplasia     1.60 ± 0.34
(n = 14)
Barrett’s metaplasia and refl ux esophagitis  1.12 ± 0.35
(n = 8)
Barrett’s metaplasia and dysplasiab  0.58 ± 0.37
(n = 7)
Adenocarcinomab,c     0.18 ± 0.25 
(n = 8) 
Histology              Score (mean ± SD)
Normal epithelium (Control goup)b  0.28 ± 0.39
(n = 7)   
Refl ux esophagitis     1.71 ± 0.39
(n = 7)
Barrett’s metaplasia     1.46 ± 0.41
(n = 14)
Barrett’s metaplasia and refl ux esophagitis  1.75 ± 0.26
(n = 8)   
Barrett’s metaplasia and dysplasiaa  2.16 ± 0.25
(n = 7)
Adenocarcinomaa,c    2.62 ± 0.35 
(n = 8)
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Although most of  the biological markers need to be 
evaluated further, at present, aneuploidy status, p16 and 
p53 gene abnormalities, or allelic losses are the most 
extensively documented alterations[33]. 
Immunostaining with a variety of  antibodies provides 
a better understanding of  the process of  malignant 
transformation and helps to identify early markers of  
malignant transformation in BE[34]. 
Given the lack in the literature of  the evaluation of  
GST and MMP-9 expressions in the same experimental 
setting, we evaluated the behaviour of  detoxification 
e n z y m e G S T, a n d o n e m e m b e r o f  t h e m a t r i x 
metalloproteinases family, MMP-9, in the development and 
progression of  normal epithelium, refl ux esophagitis, BE, 
dysplasia and adenocarcinoma sequence in the esophagus. 
A number of  findings in our study confirmed that 
GST is involved in esophageal carcinogenesis and 
progression. We have demonstrated that GST expression 
was signifi cantly higher in normal esophageal epithelium 
compared to the other groups. On the other hand, BE 
with dysplasia, and adenocarcinoma revealed a signifi cantly 
Figure 1  Expression of GST in different esophageal tissues. A: GST strong 
positive staining was observed in the normal esophagus (200 ×); B: Normal es-
ophageal epithelium (top) with Barrett’s metaplasia (bottom) (200 ×); C: Normal 
esophageal epithelium shows strong positive immunostaining compared to the 
weaker GST expression in Barrett’s metaplasia (400 ×); D: Adenocarcinoma show-
ing almost no expression of GST (200 ×); GST was mainly expressed within the 
cytoplasm.
Figure 2  Expression of MMP-9 in different esophageal tissues. Strong positive 
immunostaining of MMP-9 in (A) Barrett’s metaplasia (400 ×), (B) dysplasia (400 ×) 
and (C) adenocarcinoma (200 ×) of the esophagus. Cytoplasm of the metaplastic 
and dysplastic cells and cytoplasmic membranes of the esophageal adenocarci-
noma cells were stained brown. Barrett’s metaplasia with concomitant dysplasia 
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lower expression of  GST, while adenocarcinoma expressed 
almost no GST. 
Our findings are similar to the results reported by 
van Lieshout et al[9] and Cobbe et al[11]. They reported that 
the expression of  GST appeared to be reduced in BE 
compared to normal esophageal squamous epithelium. 
In contrast to the van Lieshout et al[9] and Cobbe et al[11] 
studies, we also demonstrated that BE with concomitant 
dysplasia, and adenocarcinoma revealed a significantly 
lower expression of  GST. Brabander et al[10] also found 
that GST expression was highest in the basal layer of  
normal esophageal squamous epithelium and lowest in 
adenocarcinoma cells, with BE cells showing intermediate 
staining intensity.
These results suggest that decreased GST expression 
could be an early event in the development of  BE and may 
contribute to the risk of  development and progression 
of  adenocarcinoma in BE. The observed reduction in 
GST expression in BE may, therefore, contribute to the 
increased risk in this tissue.
Degradation of  the ECM and basement membrane 
by tumor cells is a critical step in the process of  tumor 
invasion and metastasis. MMP-9 is one member of  the 
matrix metalloproteinases family, which is capable of  
degrading several components of  the ECM. Increased 
expression of  MMP-9 has been found in var ious 
carcinomas. With respect to the gastrointestinal tract, 
increased MMP-9 expressions have been observed in 
gastric[25-27] and colorectal cancer[35-38]. In the specific 
case of  the esophagus, increased expression of  MMP-9 
has been demonstrated in esophageal squamous cell 
carcinoma[28-30], but its role and behaviour in esophageal 
adenocarcinoma and BE is not well established. 
The relatively small number of  patients in our 
study can be explained by the known data about the 
epidemiology of  BE and esophageal adenocarcinoma 
in Hungary; since only 4% of  patients with esophageal 
cancers were diagnosed to have adenocarcinoma and its 
proportion remained stable over the observed last decade, 
it seems that contrary to North American and Western 
European countries, the prevalence of  adenocarcinoma 
has been, until now, very low in Hungary[39]. 
In the present study, immunohistochemical analysis 
revealed a progressive increase in the expression of  
MMP-9 with increasing severity of  esophageal lesions. 
MMP-9 expression was significantly lower in normal 
esophageal epithelium compared to other groups. BE 
with concomitant dysplasia revealed a signifi cantly higher 
expression of  MMP-9 compared to BE, refl ux esophagitis 
or BE with concomitant esophagitis. We observed 
that MMP-9 expression was significantly higher in 
adenocarcinoma compared to BE or BE with concomitant 
dysplasia. These results suggest that over-expression of  
MMP-9 plays an important role in the progression to 
esophageal adenocarcinoma, and MMP-9 protein may 
serve as a marker for invasiveness. Our results indicate 
that the activation of  MMP-9 may be an early event in 
esophageal carcinogenesis. 
Our findings are relevant from both, biological and 
clinical points of  view. Despite the advance in preoperative 
and postoperative medical care of  esophageal carcinoma 
patients, their prognosis has improved only marginally. 
Therefore, it would be useful to have additional biomarkers 
to help clinicians better determine the risk of  esophageal 
cancer development. In esophageal cancer, novel targeted 
treatments are still in an early phase of  development. 
It can be speculated that the relevance of  MMP-9 in 
esophageal carcinogenesis may also support a possible 
therapeutic approach[40]. Indeed, this can be obtained 
directly by inhibition of  MMP-9. Phase II-trials with the 
matrix metalloproteinase inhibitor prinomastat in patients 
with esophageal adenocarcinoma are under evaluation[41]. 
The present study showed that expressions of  GST 
and MMP-9 were reversely or negatively correlated, 
thus suggesting a concomitant down-regulation and up-
regulation, respectively, of  these systems. GST plays an 
important protective role in the prevention of  cancer 
by detoxifying potentially carcinogenic compounds, 
while MMP-9 should be considered an aggressive factor, 
playing a crucial role in the progression of  esophageal 
carcinogenesis. 
In conclusion, our results demonstrate a significantly 
lower expression of  GST and a significantly higher 
expression of  MMP-9, respectively, in the BE-dysplasia-
adenocarcinoma sequence as compared to normal 
esophageal tissue. The simultaneous down-regulation 
of  GST and up-regulation of  MMP-9 strongly suggest 
their association with esophageal tumorigenesis and 
particularly, their specifi c role in the biology of  esophageal 
adenocarcinoma. Loss of  GST and gain of  MMP-9 in BE 
with concomitant dysplasia compared to non-dysplastic 
BE indicate that these alterations may be early events in 
esophageal carcinogenesis. Together with other biological 
markers, quantifi cation of  these parameters in BE might 
be useful to identify patients at higher risk for progression 
to adenocarcinoma, to prevent tumor development and to 
improve prognosis. 
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